06.10.2021 • News

Mitsubishi Gas Expands European MXDA Capacity

Mitsubishi Gas Chemical has announced plans to expand capacity for meta-xylenediamine (MXDA) in the Netherlands. The Japanese group said the expansion will meet growth in the European epoxy, polyamide and isocyanate markets.

Through a newly established subsidiary – MGC Specialty Chemicals Netherlands – Mitsubishi Gas Chemical will build a 25,000 t/y plant in Rotterdam, with operations scheduled to start in mid-2024.

MXDA is mainly used in epoxy coatings for infrastructure applications due to its excellent anticorrosion properties, and the company expects the market to see long-term growth. The company said Europe is the largest market for MXDA, adding that its two existing plants in Mizushima and Niigata, Japan, will operate fully to serve fast-growing markets in Asia, until the new plant starts up.

Under its three-year management plant ‘Grow UP 2023’ launched in April, the Tokyo-headquartered company has defined MXDA as a “differentiating” business to which it intends to proactively allocate resources to further strengthen competitive advantage.

Author: Elaine Burridge, Freelance Journalist

Mitsubishi Gas Chemical has announced plans to expand capacity for...
Mitsubishi Gas Chemical has announced plans to expand capacity for meta-xylenediamine (MXDA) in Rotterdam, the Netherlands, in order to meet growth in the European epoxy, polyamide and isocyanate markets. The 25,000 t/y plant is due online in mid-2024. (c) Nate Watson

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read